Journal article
Treatment of spinocerebellar ataxia with buspirone
Journal of the neurological sciences, v 260(1), pp 143-146
2007
PMID: 17512011
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.
Metrics
Details
- Title
- Treatment of spinocerebellar ataxia with buspirone
- Creators
- Mitra Assadi - Cooper University HospitalJoseph V. Campellone - Cooper University HospitalChristopher G. Janson - Cooper University HospitalJ. Jon Veloski - Thomas Jefferson UniversityRobert J. Schwartzman - Drexel UniversityPaola Leone - Cooper University Hospital
- Publication Details
- Journal of the neurological sciences, v 260(1), pp 143-146
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- School of Biomedical Engineering, Science, and Health Systems; Neurology
- Web of Science ID
- WOS:000249315000022
- Scopus ID
- 2-s2.0-34547683197
- Other Identifier
- 991019167866904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Clinical Neurology
- Neurosciences